Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1

Journal of General Virology

Volumn 77, Issue 12, 1996, Pages 2931-2941

  Armstrong, Sylvia J ^a   McInerney, Tracey L ^a   McLain, Lesley ^a   Wahren, Britta ^b   Hinkula, Jorma ^b   Levi, Michael ^b   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; CELL FUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE TEST; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; VIRION; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030477534     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-77-12-2931     Document Type: Article

References (51)

1. Åkerblom, L., Hinkula, J., Broliden, P.-A., Mäkitalo, B., Fridberger, T., Rosen, J., Villacres-Erikssen, M., Morein, B. & Wahren, B. (1990). Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 4, 953-960.
2. Armstrong, S. J. & Dimmock, N. J. (1992). Neutralization of influenza virus by low concentrations of HA-specific polymeric IgA inhibits viral fusion activity but activation of the ribonucleoprotein is also inhibited. Journal of Virology 66, 3823-3832.
3. Armstrong, S. J. & Dimmock, N. J. (1996). Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: identification of a very early fusion-dependent event as a neutralization target. Journal of General Virology 77, 1397-1402.
4. Back, N. K. T., Smit, L., Schutten, M., Nara, P. L., Tersmette, M. & Goudsmit, J. (1993). Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. Journal of Virology 67, 6897-6902.
5. Benjouad, A., Chapuis, F., Fenouillet, E. & Gluckman, J.-C. (1995). Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit HIV-1 infection through interaction with CD4. Virology 206, 457-464.
6. Bukrinsky, M. I., Sharova, N., McDonald, T. L., Pushkarskaya, T., Tarpley, W. G. & Stevenson, M. (1993). Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proceedings of the National Academy of Sciences, USA 90, 6125-6129.
7. Cavacini, L. A., Emes, C. L., Power, J., Duval, M. & Posner, M. R. (1994). Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. Journal of Immunology 152, 2538-2545.
8. Clements, G. J., Price-Jones, M. J., Stephens, P. E., Sutton, C., Schultz, T. F., Clapham, P. R., McKeating, J. A., McClure, M. O., Thompson, S., Marsh, M., Kay, J., Weiss, R. A. & Moore, J. P. (1991). The V3 loops of HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion. AIDS Research and Human Retroviruses 7, 3-16.
9. Dimmock, N. J. (1993). Neutralization of animal viruses. Current Topics in Microbiology and Immunology 183, 1-149.
10. Dimmock, N. J. (1995). Update on the neutralization of animal viruses. Reviews in Medical Virology 5, 165-179.
11. Freed, E. O. & Martin, M. A. (1996). Domains on the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. Journal of Virology 70, 341-351.
12. Freed, E. O., Myers, D. J. & Risser, R. (1991). Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. Journal of Virology 65, 190-194.
13. Gallay, P., Swingler, S., Aiken, C. & Trono, D. (1995). HIV-1 infection of non-dividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80, 379-388.
14. Healy, D., Dianda, L., Moore, J. P., McDougal, J. S., Moore, M. J., Estess, P., Buck, D., Kwong, P. D., Beverley, P. C. L. & Sattentau, Q. J. (1990). Novel anti-CD4 monoclonal antibodies separate HIV infection and fusion of CD4+ cells from virus binding. Journal of Experimental Medicine 172, 1233-1242.
15. Ho, D. D., Kaplan, J. C., Rackauskas, I. E. & Gurney, M. E. (1988). Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239, 1021-1023.
16. Iorio, R. M., Glickman, R. L., Riel, A. M., Sheehan, J. P. & Bratt, M. A. (1989). Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent attachment. Virus Research 13, 245-262.
17. Laal, S., Burda, S., Gorny, M. K., Karwowska, S., Buchbinder, A. & Zolla-Pazner, S. (1994). Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. Journal of Virology 68, 4001-4008.
18. Laman, J. D., Schellens, M. M., Abacioglu, Y. H., Lewis, G. K., Tersmette, M., Fouchier, R. A. M., Langedijk, J. P. M., Claassen, E. & Boersma, W. J. A. (1992). Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. Journal of Virology 66, 1823-1831.
19. Levi, M., Sällberg, M., Rudén, U., Herlyn, D., Maruyama, H., Wigzell, H., Marks, J. & Wahren, B. (1993). A complementarity-determining region synthetic peptide acts as a mini-antibody and neutralizes human immunodeficiency virus type 1 in vitro. Proceedings of the National Academy of Sciences, USA 90, 4375-4378.
20. McDougal, J. S., Nicholson, J. K. A., Cross, G. D., Cort, S. P., Kennedy, M. S. & Mawle, A. C. (1986). Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. Journal of Immunology 137, 2937-2944.
21. McKeating, J. A., Cordell, J. A., Dean, C. J. & Balfe, P. (1992a). Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191, 732-742.
22. McKeating, J. A., Moore, J. P., Ferguson, M., Marsden, H. S., Graham, S., Almond, J. W., Evans, D. J. & Weiss, R. A. (1992b). Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS Research and Human Retroviruses 8, 451-459.
23. McKeating, J. A., Shotton, C., Cordell, J., Graham, S., Balfe, P., Sullivan, N., Charles, M., Page, M., Bolmstedt, A., Olofsson, S., Kayman, C., Wu, Z., Pinter, A., Dean, C., Sodrowski, J. & Weiss, R. A. (1993). Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology 67, 4932-4944.
24. McLain, L. & Dimmock, N. J. (1994). Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. Journal of General Virology 75, 1457-1460.
25. McLain, L. & Dimmock, N. J. (1996). A human CD4+ T cell line expresses functional CD64 (Fcγ/RI), CD32 (FcγRII), and CD16 (FcγRIII) receptors, but these do not enhance the infectivity of HIV-1-IgG complexes. Immunology (in press).
26. McLain, L., Durrani, Z., Wisniewski, L. A., Porta, C., Lomonossoff, G. P. & Dimmock, N. J. (1996). Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plant virus. Vaccine 14, 799-810.
27. Maddon, P. J., Dalgleish, A. G., McDougall, J. S., Clapham, P. R., Weiss, R. A. & Axel, R. (1986). The T4 receptor encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348.
28. Marsh, M. & Pelchen-Matthews, A. (1993). Entry of animal viruses into cells. Reviews in Medical Virology 3, 173-185.
29. Moore, J. P. & Ho, D. D. (1995). HIV-1 neutralization: the consequences of viral adaption to growth on transformed T cells. AIDS 9(Suppl. A), S117-S136.
30. Moore, J. P. & Klasse, P. J. (1992). Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and gp120 dissociation. AIDS Research and Human Retroviruses 8, 443-450.
31. Moore, J. P. & Nara, P. L. (1991). The role of the V3 loop of gp120 in HIV infection. AIDS 5(Suppl. 2), S21-S33.
32. Moore, J. P., Jameson, B. A., Weiss, R. A. & Sattentau, Q. (1993). The HIV-cell fusion reaction. In Viral Fusion Mechanisms, pp. 233-289. Edited by J. Bentz. Boca Raton, Fla.: CRC Press.
33. Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler, J. A., II, McCutchan, F. E., Mascola, J. R., Ho, D. D., Robinson, J. & Conley, A. J. (1995). A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of Virology 69, 122-130.
34. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F. & Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67, 6642-6647.
35. Outlaw, M. C. & Dimmock, N. J. (1993). IgG-neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway. Virology 195, 413-421.
36. Page, K. A., Stearns, S. M. & Littman, D. R. (1992). Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. Journal of Virology 66, 524-533.
37. Poignard, P., Klasse, P.I. & Sattentau, Q.J. (1996). Antibody neutralization of HIV-1. Immunology Today 17, 239-246.
38. Posner, M. R., Hideshima, T., Cannon, T., Mukherjee, M., Mayer, K. H. & Byrn, R. A. (1991). An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. Journal of Immunology 146, 4325-4332.
39. Potts, B. J., Field, K. G., Wu, Y. M., Posner, M., Cavacini, L. & White-Scharf, M. (1993). Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3 directed monoclonal antibodies. Virology 197, 415-419.
40. Rigg, R. J., Carver, A. S. & Dimmock, N. J. (1989). IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo. Journal of General Virology 70, 2097-2109.
41. Rusche, J. R., Javaherian, K., McDanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A. G., Gallo, R. C., Arthur, L. O., Fischinger, P. J., Bolognesi, D. P., Putney, S. D. & Matthews, T. J. (1988). Antibodies that inhibit fusion of HIV-infected cells bind to a 24 amino acid sequence of the viral envelope protein, gp120. Proceedings of the National Academy of Sciences, USA 85, 3198-3202.
42. Sattentau, Q. J. (1996). Neutralization of HIV-1 by antibody. Current Opinion in Immunology 8, 540-545.
43. Sattentau, Q. J. & Moore, J. P. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. Journal of Experimental Medicine 182, 185-196.
44. Schlesinger, J. & Ulrich, A. (1992). Growth factor signaling by receptor tyrosine kinases. Neuron 9, 267-269.
45. Schultz, T. F., Reeves, J. D., Hoad, J. G., Tailor, C., Stephens, P., Clements, G., Ortlepp, S., Page, K. A., Moore, J. P. & Weiss, R. A. (1993). Effect of mutations in the V3 loop of HIV-gp120 on infection and susceptibility to proteolytic cleavage. AIDS Research and Human Retroviruses 9, 159-166.
46. Skinner, M. A., Langlois, A. J., McDanal, C. B., McDougal, J. S., Bolognesi, D. P. & Matthews, T. J. (1988). Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. Journal of Virology 62, 4195-4200.
47. Smith, T. J., Olson, N. H., Cheng, R. H., Liu, H., Chase, E. S., Lee, W. M., Leippe, D. M., Mosser, A. G., Rueckert, R. R. & Baker, T. S. (1993). Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. Journal of Virology, 67, 1148-1158.
48. Sun, N.-C., Ho, D. D., Sun, C. R. Y., Liou, R.-S., Gordon, W., Fung, M. S. C., Li, X.-L., Ting, R. C., Lee, T.-H., Chang, N. T. & Chang, T.-W. (1989). Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. Journal of Virology 63, 3579-3585.
49. Tilley, S. A., Honnen, W. J., Racho, M. E., Chou, T.-C. & Pinter, A. (1992). Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Research and Human Retroviruses 8, 461-467.
50. White-Scharf, M. E., Potts, B. J., Smith, L. M., Sokolowski, K. A., Rusche, J. R. & Silver, S. (1993). Broadly neutralizing monoclonal antibodies to the V3 region of HIV-I can be elicited by peptide immunization. Virology 192, 197-206.
51. Wilson, M., Reitz, M. S., Aldrich, K., Klasse, P. J., Blomberg, J., Gallo, R. C. & Robert-Guroff, M. (1990). The site of an immune-selected point mutation in the transmembrane protein of the human immunodeficiency virus type 1 does not constitute the neutralization epitope. Journal of Virology 64, 3240-3248.